Phathom Pharmaceuticals (PHAT) Operating Income (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Operating Income of -$15.5 million for Q1 2026, up 80.37% year-over-year from -$8.6 million in Q1 2025, and down 161.08% quarter-over-quarter from -$5.9 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Operating Income (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Operating Income data on file, last reported at -$15.5 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$15.5 million, up 80.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$96.6 million (up 66.27% YoY), and the FY2025 annual result was -$160.0 million, up 42.34% from the prior year.
- Operating Income fell to -$15.5 million in Q1 2026 per PHAT's latest filing, from -$5.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$5.9 million in Q4 2025 and troughed at -$78.9 million in Q1 2025.
- A 5-year average of -$46.6 million and a median of -$45.4 million in 2022 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income sank 143.84% in 2024, then surged 90.02% in 2025.
- A 5-year view of Operating Income shows it stood at -$46.6 million in 2022, then plunged by 49.81% to -$69.9 million in 2023, then increased by 14.97% to -$59.4 million in 2024, then surged by 90.02% to -$5.9 million in 2025, then slumped by 161.08% to -$15.5 million in 2026.
- Business Quant data shows PHAT's Operating Income at -$15.5 million in Q1 2026, -$5.9 million in Q4 2025, and -$15.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -15.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.48 Mn |
| Dec 31, 2025 | -5.93 Mn |
| Sep 30, 2025 | -15.27 Mn |
| Jun 30, 2025 | -59.92 Mn |
| Mar 31, 2025 | -78.86 Mn |
| Dec 31, 2024 | -59.42 Mn |
| Sep 30, 2024 | -70.80 Mn |
| Jun 30, 2024 | -77.30 Mn |
| Mar 31, 2024 | -69.95 Mn |
| Dec 31, 2023 | -69.88 Mn |
| Sep 30, 2023 | -35.66 Mn |
| Jun 30, 2023 | -31.70 Mn |
| Mar 31, 2023 | -30.08 Mn |
| Dec 31, 2022 | -46.64 Mn |
| Sep 30, 2022 | -42.53 Mn |
| Jun 30, 2022 | -45.36 Mn |
| Mar 31, 2022 | -37.91 Mn |
| Dec 31, 2021 | -33.04 Mn |
| Sep 30, 2021 | -33.14 Mn |
| Jun 30, 2021 | -35.32 Mn |